Tango Therapeutics, Inc. is a Pharmaceuticals company based in the United States of America. With a Risk Rating Score of 29.6, the company is considered to have a Medium Risk level. Specializing in precision oncology therapies, Tango Therapeutics is dedicated to discovering novel drug targets for the treatment of cancer. Their program TNG908 focuses on developing MTA-cooperative inhibitors for cancer cells with an MTAP deletion. Explore their pipeline of discovery programs like TNG462, TNG348, and TNG260 for various types of cancer with limited treatment options. Prioritize ESG principles with Tango Therapeutics for cutting-edge precision medicine solutions.